MS Treatment Not Seen to Improve Walking Ability in CP Patients in Clinical Trial
Although dalfampridine extended-release treatment was found safe and well-tolerated in a pilot study in adults with cerebral palsy (CP), the drug failed to show any impact on walking ability. Although the trial, which focused on adult CP patients with walking difficulties, was small, the lack of benefits prompted researchers to…